PAP
Persistent Asset Partners Portfolio holdings
AUM
$138M
1-Year Est. Return
38.77%
1 Year Est. Return
+38.77%
AUM
$138M
AUM Growth
+$23.9M
(+21%)
Holding
264
Top Buys
| 1 | +$8.19M | |
| 2 | +$4.82M | |
| 3 | +$4.17M | |
| 4 |
CVS Health
CVS
|
+$3.89M |
| 5 |
NBIS
Nebius Group N.V.
NBIS
|
+$3.37M |
Top Sells
| 1 | +$4.91M | |
| 2 | +$3.58M | |
| 3 | +$3.43M | |
| 4 |
Amgen
AMGN
|
+$3.35M |
| 5 |
Eli Lilly
LLY
|
+$2.65M |
Sector Composition
| 1 | Healthcare | 51.53% |
| 2 | Financials | 14.56% |
| 3 | Technology | 6.97% |
| 4 | Consumer Discretionary | 6.12% |
| 5 | Materials | 5.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
UMB Financial
UMBF
$8.43B
| – | – |
-9,391
|
|
||
|
VBTX
252
DELISTED
Veritex Holdings
VBTX
| – | – |
-7,980
|
|
||
253
Viridian Therapeutics
VRDN
$2.9B
| – | – |
-28,032
|
|
||
254
Vertex Pharmaceuticals
VRTX
$110B
| – | – |
-2,303
|
|
||
255
State Street SPDR NYSE Technology ETF
XNTK
$1.48B
| – | – |
0
|
|
||
256
Zillow
Z
$17.4B
| – | – |
-3,071
|
|
||
257
Zai Lab
ZLAB
$2.16B
| – | – |
-873
|
|
||
258
Skye Bioscience
SKYE
$35.6M
| – | – |
0
|
|
||
259
Zeekr
ZK
$6.84B
| – | – |
-10,000
|
|
||
|
ATYR
260
aTyr Pharma
ATYR
$69.1M
| – | – |
0
|
|
||
|
TECX
261
Tectonic Therapeutic
TECX
$356M
| – | – |
0
|
|
||
|
MBX
262
MBX Biosciences
MBX
$1.49B
| – | – |
0
|
|
||
|
UPB
263
Upstream Bio Inc
UPB
$1.35B
| – | – |
0
|
|